Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout
– Data demonstrate SEL-212 efficacy, reduction in the incidence of gout flares and support for dose selection in the ongoing […]